IL-6 receptor is a possible target against growth of metastasized lung tumor cells in the brain

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 515-526

  Noda, Mami ^a   Yamakawa, Yukiko ^a   Matsunaga, Naoya ^a   Naoe, Satoko ^a   Jodoi, Taishi ^a   Yamafuji, Megumi ^a   Akimoto, Nozomi ^a   Teramoto, Norihiro ^b   Fujita, Kyota ^a   Ohdo, Shigehiro ^a   Iguchi, Haruo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Anti IL 6R antibody; Astrocytes; Brain metastasis; HARA B cells; Lung cancer; Tumor microenvironment

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6 RECEPTOR ALPHA; TOCILIZUMAB; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN METASTASIS; CADAVER; CANCER INHIBITION; CELL ACTIVATION; CELL INTERACTION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; POSTMORTEM CHANGE; SECONDARY; TUMOR CELL LINE;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTROCYTES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; HUMANS; LUNG NEOPLASMS; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR TARGETED THERAPY; POSTMORTEM CHANGES; RECEPTORS, INTERLEUKIN-6;

EID: 84872202767     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14010515     Document Type: Article

References (42)

1. Fidler, I.J.; Yano, S.; Zhang, R.D.; Fujimaki, T.; Bucana, C.D. The seed and soil hypothesis: Vascularisation and brain metastases. Lancet Oncol. 2002, 3, 53-57.
2. Steeg, P.S.; Camphausen, K.A.; Smith, Q.R. Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 2011, 11, 352-363.
3. Aloisi, F.; Ria, F.; Adorini, L. Regulation of t-cell responses by cns antigen-presenting cells: Different roles for microglia and astrocytes. Immunol. Today 2000, 21, 141-147.
4. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to virchow? Lancet 2001, 357, 539-545.
5. Fitzgerald, D.P.; Palmieri, D.; Hua, E.; Hargrave, E.; Herring, J.M.; Qian, Y.; Vega-Valle, E.; Weil, R.J.; Stark, A.M.; Vortmeyer, A.O.; et al., Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metastasis 2008, 25, 799-810.
6. Noda, M. The brain microenvironment. In Brain and Central Nervous System Metasitasis, the Biological Basis and Clinical Considerations; Palmieri, D., Ed.; Springer: New York, NY, USA, 2012.
7. Heyn, C.; Ronald, J.A.; Ramadan, S.S.; Snir, J.A.; Barry, A.M.; MacKenzie, L.T.; Mikulis, D.J.; Palmieri, D.; Bronder, J.L.; Steeg, P.S.; et al. In vivo mri of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn. Reson. Med. 2006, 56, 1001-1010.
8. Seike, T.; Fujita, K.; Yamakawa, Y.; Kido, M.A.; Takiguchi, S.; Teramoto, N.; Iguchi, H.; Noda, M. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin. Exp. Metastasis 2011, 28, 13-25.
9. Maini, R.N.; Taylor, P.C.; Szechinski, J.; Pavelka, K.; Broll, J.; Balint, G.; Emery, P.; Raemen, F.; Petersen, J.; Smolen, J.; et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54, 2817-2829.
10. Mihara, M.; Nishimoto, N.; Ohsugi, Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin. Biol. Ther. 2005, 5, 683-690.
11. Ding, C.; Jones, G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 2006, 1, 193-200.
12. Yokota, S.; Miyamae, T.; Imagawa, T.; Iwata, N.; Katakura, S.; Mori, M.; Woo, P.; Nishimoto, N.; Yoshizaki, K.; Kishimoto, T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005, 52, 818-825.
13. Yokota, S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr. Opin. Rheumatol. 2003, 15, 581-586.
14. Straub, R.H.; Harle, P.; Yamana, S.; Matsuda, T.; Takasugi, K.; Kishimoto, T.; Nishimoto, N. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006, 54, 1778-1785.
15. Plushner, S.L. Tocilizumab: An interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann. Pharmacother. 2008, 42, 1660-1668.
16. Nishimoto, N.; Yoshizaki, K.; Miyasaka, N.; Yamamoto, K.; Kawai, S.; Takeuchi, T.; Hashimoto, J.; Azuma, J.; Kishimoto, T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50, 1761-1769.
17. Nishimoto, N.; Yoshizaki, K.; Maeda, K.; Kuritani, T.; Deguchi, H.; Sato, B.; Imai, N.; Suemura, M.; Kakehi, T.; Takagi, N.; et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody mra in rheumatoid arthritis. Phase i/ii clinical study. J. Rheumatol. 2003, 30, 1426-1435.
18. Mihara, M.; Kotoh, M.; Nishimoto, N.; Oda, Y.; Kumagai, E.; Takagi, N.; Tsunemi, K.; Ohsugi, Y.; Kishimoto, T.; Yoshizaki, K.; et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol. 2001, 98, 319-326.
19. Choy, E.H.; Isenberg, D.A.; Garrood, T.; Farrow, S.; Ioannou, Y.; Bird, H.; Cheung, N.; Williams, B.; Hazleman, B.; Price, R.; et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002, 46, 3143-3150.
20. Ito, H. Novel therapy for crohn's disease targeting il-6 signalling. Expert Opin. Ther. Targets 2004, 8, 287-294.
21. Nishimoto, N.; Kanakura, Y.; Aozasa, K.; Johkoh, T.; Nakamura, M.; Nakano, S.; Nakano, N.; Ikeda, Y.; Sasaki, T.; Nishioka, K.; et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric castleman disease. Blood 2005, 106, 2627-2632.
22. Nishimoto, N. Clinical studies in patients with castleman's disease, crohn's disease, and rheumatoid arthritis in japan. Clin. Rev. Allergy Immunol. 2005, 28, 221-230.
23. Kawabe, T.; Phi, J.H.; Yamamoto, M.; Kim, D.G.; Barfod, B.E.; Urakawa, Y. Treatment of brain metastasis from lung cancer. Prog. Neurol. Surg. 2012, 25, 148-155.
24. Xu, Z.; Elsharkawy, M.; Schlesinger, D.; Sheehan, J. Gamma knife radiosurgery for resectable brain metastasis. World Neurosurg. 2012, in press.
25. Padovani, L.; Muracciole, X.; Regis, J. Gamma knife radiosurgery of brain metastasis from breast cancer. Prog. Neurol. Surg. 2012, 25, 156-162.
26. Marchan, E.M.; Sheehan, J. Stereotactic radiosurgery of brain metastasis from melanoma. Prog. Neurol. Surg. 2012, 25, 176-189.
27. Kelly, P.J.; Lin, Y.B.; Yu, A.Y.; Alexander, B.M.; Hacker, F.; Marcus, K.J.; Weiss, S.E. Stereotactic irradiation of the postoperative resection cavity for brain metastasis: A frameless linear accelerator-based case series and review of the technique. Int. J. Radiat. Oncol. Biol., Phys. 2012, 82, 95-101.
28. Momiyama, M.; Suetsugu, A.; Kimura, H.; Kishimoto, H.; Aki, R.; Yamada, A.; Sakurada, H.; Chishima, T.; Bouvet, M.; Endo, I.; et al. Imaging the efficacy of uvc irradiation on superficial brain tumors and metastasis in live mice at the subcellular level. J. Cell. Biochem. 2012, 114, 428-434.
29. Huang, J.; Dong, X.R.; Lu, H.D.; Liu, L. A case report: Successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer. West Indian Med. J. 2012, 61, 106-108.
30. Li, G.H.; Liu, Y.; Tang, J.L.; Zhang, D.; Zhou, P.; Yang, D.Q.; Ma, C.K. Pulsed reduced dose-rate radiotherapy as re-irradiation for brain metastasis in a patient with lung squamous-celled carcinoma. Jpn. J. Clin. Oncol. 2012, 42, 856-860.
31. Khan, E.; Ismail, S.; Muirhead, R. Incidence of symptomatic brain metastasis following radical radiotherapy for non-small cell lung cancer: Is there a role for prophylactic cranial irradiation? Bri. J. Radiol. 2012, doi:10.1259/bjr/23314501.
32. Preusser, M.; Berghoff, A.S.; Schadendorf, D.; Lin, N.U.; Stupp, R. Brain metastasis: Opportunity for drug development? Curr. Opin. Neurol. 2012, 25, 786-794.
33. Chen, L.T.; Xu, S.D.; Xu, H.; Zhang, J.F.; Ning, J.F.; Wang, S.F. Microrna-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med. Oncol. 2012, 29, 1673-1680.
34. Hwang, S.J.; Seol, H.J.; Park, Y.M.; Kim, K.H.; Gorospe, M.; Nam, D.H.; Kim, H.H. Microrna-146a suppresses metastatic activity in brain metastasis. Mol. Cells 2012, 34, 329-334.
35. Soffietti, R.; Trevisan, E.; Ruda, R. Targeted therapy in brain metastasis. Curr. Opin. Oncol. 2012, 24, 679-686.
36. Lee, S.H. Role of chemotherapy on brain metastasis. Prog. Neurol. Surg. 2012, 25, 110-114.
37. Lyons, S.A.; Kettenmann, H. Oligodendrocytes and microglia are selectively vulnerable to combined hypoxia and hypoglycemia injury in vitro. J. Cereb. Blood Flow Metab. 1998, 18, 521-530.
38. Noda, M.; Nakanishi, H.; Nabekura, J.; Akaike, N. Ampa-kainate subtypes of glutamate receptor in rat cerebral microglia. J. Neurosci. 2000, 20, 251-258.
39. Kim, S.; Gaber, M.W.; Zawaski, J.A.; Zhang, F.; Richardson, M.; Zhang, X.A.; Yang, Y. The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial. Biomaterials 2009, 30, 4743-4751.
40. + cells in the development of antitumor immunity. Cancer Res. 2004, 64, 1130-1139.
41. Schwartz, L.H.; Ginsberg, M.S.; DeCorato, D.; Rothenberg, L.N.; Einstein, S.; Kijewski, P.; Panicek, D.M. Evaluation of tumor measurements in oncology: Use of film-based and electronic techniques. J. Clin. Oncol. 2000, 18, 2179-2184.
42. Kim, S.A.; Kim, Y.C.; Kim, S.W.; Lee, S.H.; Min, J.J.; Ahn, S.G.; Yoon, J.H. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin. Cancer Res. 2007, 13, 253-259.